Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLS240 in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease
NCT07890584Phase 3Not yet recruiting
- Sponsor
- Pathalys Pharma
- Start
- Oct 2026
- Primary completion
- Feb 2032
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of upacicalcet in secondary hyperparathyroidism (SHPT) (3 arms), sponsored by Pathalys Pharma. Primary endpoint: Incidence of treatment-emergent adverse events at Week 32. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
upacicalcet
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT07890584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07890584.